title: Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure.
abstract: We evaluated the effects of intravenous hydralazine (5 to 30 mg) and oral nifedipine (20 to 80 mg) on plasma catecholamines, renin, and aldosterone in 18 patients with severe chronic heart failure. Both drugs resulted in a significant decrease in systemic vascular resistance and mean systemic blood pressure, and led to an increase in cardiac output. Baseline plasma norepinephrine concentration was elevated in most patients; however, augmentation of cardiac output with both drugs did not decrease the values of this hormone (from 870 +/- 128 to 946 +/- 161 pg/ml with hydralazine and from 1088 +/- 260 to 1106 +/- 187 pg/ml with nifedipine). Plasma epinephrine level was also elevated at baseline and did not change significantly following nifedipine therapy (164 +/- 44 vs 199 +/- 54 pg/ml), but increased in most patients following the administration of hydralazine (from 105 +/- 45 to 153 +/- 27 pg/ml, p less than 0.01). The renin-aldosterone system was activated in our patients and also demonstrated a different response to both drugs. Hydralazine therapy did not change either the plasma renin concentration (30 +/- 7 vs 28 +/- 7 ng/ml/hr) or the aldosterone level (24 +/- 7 vs 22 +/- 5 ng/dl). In contrast, nifedipine increased the plasma renin concentration (22 +/- 7 to 29 +/- 8 ng/ml/hr, p less than 0.05). This change did not correlate with changes in systemic blood pressure (r = 0.03) and was probably the result of previously shown calcium blockade-mediated stimulation of renin release from the juxtaglomerular cells of the kidney.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: U
authors.initials: U
authors.lastname: Elkayam
authors.forename: A
authors.initials: A
authors.lastname: Roth
authors.forename: W
authors.initials: W
authors.lastname: Hsueh
authors.forename: L
authors.initials: L
authors.lastname: Weber
authors.forename: L
authors.initials: L
authors.lastname: Freidenberger
authors.forename: S H
authors.initials: SH
authors.lastname: Rahimtoola
mesh_terms: D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D002395:Catecholamines / Q000097:blood; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000097:blood; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018377:Neurotransmitter Agents / Q000097:blood*; D009543:Nifedipine / Q000008:administration & dosage / Q000627:therapeutic use*; D009638:Norepinephrine / Q000097:blood; D012083:Renin / Q000097:blood
chemical_list: D002395:Catecholamines; D018377:Neurotransmitter Agents; D006830:Hydralazine; D000450:Aldosterone; D012083:Renin; D009543:Nifedipine; D009638:Norepinephrine; D004837:Epinephrine